Reata Pharmaceuticals Inc

Reata Pharmaceuticals — Q1 2021 Earnings Presentation

36 slides from Reata Pharmaceuticals's earnings presentation, May 6, 2021

  1. Slide 1: 1st Quarter 2021 Financial Results and Update on Clinical Development Programs

    1st Quarter 2021 Financial Results and Update on Clinical Development Programs May 6, 2021 Exhibit 99.2

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains certain “forward-looking” statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical or present facts, are forward-looking statement

  3. Slide 3: Today's Agenda

    Opening Remarks | Warren Huff, CEO Program Updates | Colin Meyer, MD, Chief R&D Officer Chronic Kidney Disease Pipeline Neurology Pipeline Commercial Readiness Update | Dawn Bir, CCO Financial & Operational Update | Manmeet Soni, COO & CFO Concluding Remarks | Warren Huff, CEO Today’s Agenda 3

  4. Slide 4: Reata's First NDA Accepted for Filing

    Reata’s first NDA accepted for filing by FDA for bardoxolone for treatment of patients with CKD caused by Alport syndrome FDA: U.S. Food and Drug Administration; NDA: New Drug Application; PDUFA: Prescription Drug User Fee Act; Bardoxolone: bardoxolone methyl; CKD: chronic kidney disease Reata’s Fir

  5. Slide 5: Reata at a Glance

    Reata at a Glance CKD Pipeline Reata’s first NDA accepted for filing for bardoxolone in Alport syndrome Enrolled >290 patients in FALCON, expect enrollment completion by end of 2021 MERLIN data expected 2H21 Neurology Pipeline Type C meeting request granted with the FDA in 2Q21 to discuss the Delaye

  6. Slide 6: Chronic Kidney Disease Pipeline

    Chronic Kidney Disease Pipeline

  7. Slide 7: Alport Syndrome

    Alport Syndrome Dal CARDINAL EAGLE

  8. Slide 8: Alport Syndrome is One of the Most Rapidly Progressive Forms of CKD

    Alport Syndrome is One of the Most Rapidly Progressive Forms of CKD 1.CANVAS trial: Perkovic (2018); 2AASK trial: Wright (2002); 3REPRISE trial: Torres (2017); 4CKiD study: Ng (2019); 5ATHENA trial: Rheault (2016); 6CARDINAL trial, historical eGFR, Chertow et al., Am J Nephrol (2021); Units of mL/mi

  9. Slide 9: Alport Syndrome Patients Progress Rapidly to Kidney Failure

    Alport Syndrome Patients Progress Rapidly to Kidney Failure 9 Solid lines depict annualized longitudinal estimates of eGFR decline based on historical eGFR data from up to 5 years prior to study entry in CARDINAL Phase 3; Chertow et al., Am J Nephrol (2021); ESKD: end-stage kidney disease eGFR (mL/m

  10. Slide 10: Years Lost: Life Expectancy Decreased by 40 Years in Young Patients

    10 Years Lost Most Severe Alport Syndrome Population Life Expectancy Decreased by 40 Years in Young Patients who Reach Kidney Failure Age at ESKD Onset United States Renal Data System (USRDS) Report, 2018

  11. Slide 11: Chronic Inflammation Drives CKD Progression

    Chronic Inflammation Drives CKD Progression Nrf2 promotes resolution of inflammation and is suppressed in many forms of CKD Genome-wide analyses validate association between impaired Nrf2 activity and reduced kidney function across nine forms of CKD, including Alport syndrome9 1Cuadrado et al., Nat

  12. Slide 12: Bardoxolone Suppresses Inflammation to Restore Kf and Increase SNGFR

    Through Activation of Nrf2 Bardoxolone Suppresses Inflammation to Acutely Restore Kf and Increase SNGFR Preclinical animal data; 1Kidokoro et al., ASN (2019); 2Ding et al., Kindey International (2013) Increase SNGFR by Restoring Glomerular Surface Area (Kf)1,2 No Effects on Afferent or Efferent Vasc

  13. Slide 13: Bardoxolone Pharmacologically Increases UACR

    Bardoxolone Pharmacologically Increases UACR by Increasing Filtration and Decreasing Reabsorption Preclinical animal data; 1Kashihara et al., ASN (2019); 2Reisman et al., JASN (2012); 3Rossing et al., Kidney International (2019); UACR: urine albumin-to-creatinine ratio 13 Increases in UACR are a pha

  14. Slide 14: Bardoxolone and Analogs Reduce Fibrosis in CKD Models

    Bardoxolone and Analogs Reduce Fibrosis in CKD Models 1Aminzadeh, Redox Biol (2013); 2Hisamichi, Hypertension Res (2018); 3Zoja, ASN (2010); 4Nagasu, FASEB J (2019); 5Tan, Diabetes (2014); 6Wu, Arthritis Rheumatol (2014); Ald: Aldosterone; ICGN: immune complex-mediated glomerulonephritis; ApoE: apol

  15. Slide 15: Overview of Bardoxolone Clinical Efficacy

    Overview of Bardoxolone Clinical Efficacy 15 Significant On-treatment Benefit Sustained for 2 Years Consistent On- and Off-Treatment Benefit vs Placebo in Other CKD Trials 1Change in eGFR and corresponding p-value are relative to baseline; ITT: intention-to-treat; mITT: modified intention-to-treat

  16. Slide 16: Bardoxolone Clinical Trial Safety Overview

    Bardoxolone Clinical Trial Safety Overview AEs mild to moderate, generally occur within first 12 weeks, are reversible, and are not life-threatening No evidence of safety findings in discontinued bardoxolone patients​ Received on average 33 weeks of treatment Kidney function at the end of the trial

  17. Slide 17: Other Forms of CKD

    Other Forms of CKD

  18. Slide 18: FALCON Phase 3 Study of Bardoxolone in ADPKD

    FALCON Phase 3 Study of Bardoxolone in ADPKD Phase 3 similar in design to CARDINAL with two-year treatment duration​ Planning to enroll approximately 550 patients across approximately 100 sites in the U.S., Europe, Australia, and Japan​ eGFR 30-90 mL/min​ Age 18-70 years old​ Primary endpoint: off-t

  19. Slide 19: MERLIN Phase 2 Study in CKD at Risk for Rapid Progression

    MERLIN Phase 2 Study of Bardoxolone in Patients with CKD at Risk for Rapid Progression Proof of concept, Phase 2 trial to evaluate the safety and efficacy of bardoxolone in patients at risk of rapidly progressing CKD due to multiple etiologies Multi-center, double-blind, placebo-controlled Planning

  20. Slide 20: Neurology Pipeline

    Neurology Pipeline EOS

  21. Slide 21: Omaveloxolone in Friedreich's Ataxia

    Omaveloxolone in Friedreich’s Ataxia

  22. Slide 22: Omaveloxolone Next Steps

    FDA granted Type C meeting request, scheduled to occur in 2Q21, to discuss Delayed-Start Analyses Friedreich’s ataxia development program Plan to initiate a second pivotal study in 4Q21, following discussions with FDA and EMA Omaveloxolone Next Steps EMA: European Medicines Agency 22

  23. Slide 23: Omaveloxolone Pharmacology May Be Applicable to a Broad Set of Neurological Diseases

    Omaveloxolone Pharmacology May Be Applicable to a Broad Set of Neurological Diseases Yang et al., PLoS One (2009); Neymotin et al., Free Rad Bio (2011); Dinkova-Kostova et al., (2015); Stack et al., Free Rad Biol Med 49 (2010); Dumont et al., J Neurochem (2009); Kim et al., Cells (2019); Shekh-Ahmad

  24. Slide 24: RTA HSP90 Modulator for Diabetic Neuropathy

    RTA 901 HSP90 Modulator for Diabetic Neuropathy

  25. Slide 25: RTA 901: Phase 2 Study in Diabetic Peripheral Neuropathic Pain Planned for 4Q21

    RTA 901: Phase 2 Study in Diabetic Peripheral Neuropathic Pain Planned for 4Q21 Approximately 4 million patients in the U.S. are affected with moderate or severe diabetic peripheral neuropathic pain (DPNP)1-3 Phase 1 SAD/MAD study in healthy adult volunteers demonstrated an acceptable PK profile wit

  26. Slide 26: Commercial Readiness Update

    Commercial Readiness Update

  27. Slide 27: Preparation for Reata's Alport Syndrome Launch Success

    Preparation for Reata’s Alport Syndrome Launch Success 27 Launch Readiness Market Readiness Priorities

  28. Slide 28: A Significant Launch and Near-Term Commercial Opportunity

    A Significant Launch and Near-Term Commercial Opportunity Alport Syndrome Patients Located and Nephrologists Identified 28 Alport Syndrome Patients & Treaters Alport Syndrome Market Influencers4 Pediatric and adult nephrologists viewed as influencers or experts in Alport syndrome 1Alport Syndrome Fo

  29. Slide 29: Commercial Readiness to Date

    29 Commercial Readiness to Date Commercial Launch Preparation Continues Sales Force Launch Payer Field Team Disease Awareness Continued Launch Preparation

  30. Slide 30: Financial & Operation Update

    Financial & Operation Update

  31. Slide 31: Financial Summary Q1 2021

    Financial Summary Q1 2021 Cash & Shares Cash $777.6M Total Shares Outstanding 36.3M 31.4M class A shares outstanding 4.9M class B shares outstanding 1Excludes stock-based compensation expenses; 2 GAAP and non-GAAP net loss in the first quarter of 2020 incudes the recognition of $22.2 million tax ben

  32. Slide 32: Reconciliation of GAAP to Non-GAAP Financial Measures

    Reconciliation of GAAP to Non-GAAP Financial Measures 32

  33. Slide 33: Bardoxolone Operational Readiness

    33 Manufacturing Operational Readiness Infrastructure Medical Affairs & Health Economics Educating nephrology community Bardoxolone Operational Readiness On track for planned clinical and commercial launch drug supplies Building capabilities to support global commercial entity Establishing necessary

  34. Slide 34: Concluding Remarks

    Concluding Remarks

  35. Slide 35: Key Goals Update

    35 1Kyowa Kirin, Co. is Reata’s licensee in Asia; AYAME is a study sponsored by Kyowa Kirin, Co. Key Goals Update

  36. Slide 36: Q & A

    Q & A

Reata Pharmaceuticals — Q1 2021 Earnings Presentation on 6ix